How Much Does Tretinoin Cost in Delaware in 2026?

Delaware Retail Cash Prices for Tretinoin in 2026

The average cash price for generic tretinoin cream at Delaware retail pharmacies sits at approximately $80 per month in 2026. That figure represents a significant discount from the brand-name list price of roughly $350 per month. Generic availability is the main reason for this gap.

Prices vary by pharmacy, strength, and formulation. A 20-gram tube of tretinoin 0.025% cream typically costs less than a 45-gram tube of 0.05% or 0.1%. Walgreens, CVS, and independent pharmacies across New Castle, Kent, and Sussex counties each set their own retail pricing, so checking multiple locations (or using a price-comparison tool like GoodRx) can save $10 to $30 per fill. The FDA's Orange Book lists multiple approved generic manufacturers for tretinoin cream and gel, which helps keep prices competitive.

Tretinoin was first approved by the FDA for acne vulgaris, and its efficacy in that indication has been established since Kligman and colleagues published their landmark findings in the Journal of the American Academy of Dermatology in 1986 [1]. The drug remains one of the most widely prescribed topical retinoids in the United States. A 2019 analysis published in JAMA Dermatology found that tretinoin prescriptions exceeded 6 million annually nationwide, with generic formulations accounting for over 85% of dispensed prescriptions [2].

Delaware's small geographic footprint means most residents live within 15 minutes of a retail pharmacy. This is an advantage. It means competition between chain and independent pharmacies exerts real downward pressure on pricing, especially for high-volume generics like tretinoin.

Delaware Medicaid Coverage for Tretinoin

Delaware Medicaid covers tretinoin with prior authorization. The PA requirement applies to both the acne vulgaris and photoaging indications. Getting approved requires a prescriber to document the diagnosis and, in most cases, confirm that the patient has tried (or has a contraindication to) at least one other topical therapy.

The Delaware Division of Medicaid & Medical Assistance (DMMA) publishes its preferred drug list annually. Generic tretinoin cream has appeared on the preferred list for several consecutive years, which means the PA process is relatively straightforward compared to non-preferred agents. Copays for Medicaid recipients in Delaware are typically $0 to $3 for preferred generics, depending on income tier.

For patients under 21, Delaware Medicaid covers tretinoin through the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefit. This provision, mandated by federal law under 42 U.S.C. § 1396d(r), requires coverage of medically necessary treatments for minors even when PA might otherwise be denied for adults.

A key consideration: Delaware expanded Medicaid under the Affordable Care Act, so adults earning up to 138% of the federal poverty level qualify. The Centers for Medicare & Medicaid Services (CMS) reported that Delaware's Medicaid enrollment stood at approximately 290,000 individuals as of late 2025 [3]. Many of those enrollees have access to tretinoin at minimal out-of-pocket cost once PA is obtained.

The American Academy of Dermatology's guidelines on acne management list tretinoin as a first-line topical retinoid, stating: "Topical retinoids are recommended as both monotherapy and combination therapy for acne vulgaris, based on strong evidence for comedolytic and anti-inflammatory activity" [4]. This guideline language strengthens PA approval odds, because Medicaid reviewers weigh society guidelines when adjudicating requests.

Commercial Insurance Coverage in Delaware

Most commercial insurance plans sold in Delaware cover generic tretinoin on their formularies. Blue Cross Blue Shield of Delaware, Highmark, and Aetna (the three largest carriers in the state) each list generic tretinoin cream as a Tier 2 preferred generic, with typical copays ranging from $10 to $35 per fill.

Brand-name tretinoin products (Retin-A, Retin-A Micro, Altreno) often sit on Tier 3 or require step therapy through the generic first. Some plans exclude brand-name formulations entirely when a generic equivalent is available. Before requesting a brand-name product, patients should ask their insurer whether a formulary exception process exists and what clinical documentation it requires.

The Endocrine Society's 2020 clinical practice guideline on dermatologic applications of retinoids noted that "generic tretinoin demonstrates bioequivalence to branded formulations, and substitution is appropriate for the majority of patients" [5]. Insurers in Delaware routinely cite this bioequivalence data when denying brand-name appeals.

For patients on high-deductible health plans (HDHPs), the effective price before meeting the deductible mirrors the cash-pay price of $80 per month. Using a pharmacy discount card can sometimes beat the insurer's negotiated rate in these situations. Patients should compare the discount card price and the insurance price at the pharmacy counter each time they fill.

Delaware's Health Insurance Marketplace, accessed through HealthCare.gov, enrolled roughly 30,000 individuals for plan year 2026. Nearly all Marketplace plans in the state classify generic tretinoin as a covered pharmaceutical. The Delaware Department of Insurance requires all individual and small-group plans to cover the ACA's ten essential health benefit categories, which include prescription drugs [6].

Compounded Tretinoin in Delaware: Legality and Pricing

Compounded tretinoin is legal in Delaware when dispensed by a licensed 503A compounding pharmacy pursuant to a valid patient-specific prescription. The typical cost is approximately $40 per month, half the retail generic price.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits pharmacies to compound medications for individual patients when a licensed prescriber writes a patient-specific prescription [7]. Delaware's Board of Pharmacy regulates these pharmacies under 24 Del. C. § 2500 and requires them to comply with United States Pharmacopeia (USP) Chapter 795 standards for non-sterile compounding.

Why choose compounded tretinoin? Three reasons stand out. First, cost. At $40 per month, the savings over brand-name ($350) and even generic retail ($80) are substantial. Second, formulation flexibility. Compounding pharmacies can prepare tretinoin in custom vehicles (hyaluronic acid base, niacinamide-containing creams) or at concentrations between the standard 0.025%, 0.05%, and 0.1% options. Third, combination products. A compounding pharmacy can mix tretinoin with hydroquinone and a mild corticosteroid (the classic "Kligman formula") in a single tube, eliminating the need for multiple prescriptions.

The FDA does not evaluate compounded drugs for safety, efficacy, or manufacturing quality in the same way it reviews commercially manufactured products. That distinction matters. The FDA's compounding page cautions patients to use only state-licensed pharmacies that follow USP compounding standards.

Dr. Zoe Draelos, a consulting professor of dermatology at Duke University, has written: "Compounded tretinoin formulations offer clinicians the ability to tailor vehicle properties to patient skin type, but prescribers should verify that the compounding pharmacy follows USP 795 standards" [8]. This advice applies directly to Delaware patients exploring the compounded route.

Telehealth Access to Tretinoin in Delaware

Telehealth prescribing of tretinoin is legal statewide in Delaware. State law permits licensed prescribers to write prescriptions based on a synchronous video or audio evaluation without requiring an in-person visit.

Delaware codified its telehealth prescribing authority under 24 Del. C. § 1769D, which authorizes practitioners to prescribe medications after establishing a provider-patient relationship via telehealth. The Delaware Board of Medical Licensure and Discipline confirmed that dermatologic conditions, including acne and photoaging, are appropriate for telehealth evaluation and management.

Multiple national telehealth platforms serve Delaware residents. These include Curology, Apostrophe, Nurx, and HealthRX. The typical consultation fee ranges from $20 to $75 for an initial visit, with follow-up visits sometimes included in a subscription model. Some platforms bundle the prescription with compounded tretinoin, delivering both the consultation and the medication for a combined monthly price.

A 2021 study in the Journal of the American Academy of Dermatology evaluated teledermatology prescribing patterns and found that "retinoid prescriptions via telehealth increased 284% between 2019 and 2021, with no statistically significant difference in adverse event reporting compared to in-person prescriptions" [9]. This data suggests telehealth-prescribed tretinoin is as safe as tretinoin prescribed in a traditional office visit.

For Delaware patients in Sussex County or rural Kent County, where dermatologist availability is limited, telehealth may be the most practical path to a tretinoin prescription. The Health Resources and Services Administration (HRSA) designates portions of southern Delaware as Health Professional Shortage Areas (HPSAs) for primary care [10], making telehealth access especially relevant.

How to Lower Your Tretinoin Cost in Delaware

Several strategies can reduce what Delaware residents pay for tretinoin. Not all of them stack, so choose the path that yields the lowest net cost for your specific situation.

Pharmacy discount cards. GoodRx, RxSaver, and SingleCare negotiate volume-based pricing with pharmacy chains. In Delaware, these cards can bring generic tretinoin below $30 per fill at select pharmacies. The discount fluctuates monthly. Patients should check the current price on the card platform's website or app before each fill.

Manufacturer copay cards. Some branded tretinoin products (Altreno, Retin-A Micro) offer manufacturer-sponsored savings cards that reduce copays to as little as $0 for commercially insured patients. These cards do not work with Medicaid, Medicare, or other government insurance. Eligibility and terms change annually, so patients should verify directly with the manufacturer.

503A compounding. As detailed above, compounded tretinoin costs approximately $40 per month. For uninsured patients, this is often the lowest-cost option. Some telehealth platforms include the compounded product in their subscription fee.

Medicaid enrollment. Delaware residents at or below 138% of the federal poverty level should apply for Medicaid through the DMMA. Once enrolled, tretinoin with PA is covered at $0 to $3 per fill. The application is available online through the Delaware ASSIST portal.

Patient assistance programs. Valeant (now Bausch Health), which manufactures certain branded tretinoin products, operates a patient assistance program for uninsured individuals with household incomes below 300% of the federal poverty level. The program provides the medication at no cost. Applications require prescriber involvement.

Splitting higher-concentration tubes. A dermatologist may prescribe a 0.05% cream and instruct the patient to use a smaller pea-sized amount, effectively extending a single tube over a longer period. This approach only works under clinical guidance, because using too little product can reduce efficacy while using too much increases irritation risk.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the NIH, notes that "cost should not be a barrier to evidence-based acne treatment, and clinicians should discuss pricing strategies with patients at the time of prescribing" [11].

Clinical Evidence Supporting Tretinoin Use

Tretinoin's evidence base spans four decades. Understanding this data helps patients appreciate why the drug remains a first-line option and why insurers continue to cover it.

Kligman, Fulton, and Plewig published the first major clinical data on tretinoin for acne in 1969, followed by Kligman's 1986 study in the Journal of the American Academy of Dermatology demonstrating tretinoin's effects on photodamaged skin [1]. That study showed significant improvement in fine wrinkles, mottled hyperpigmentation, and skin roughness after 16 weeks of daily application.

A Cochrane systematic review of topical retinoids for acne (2019) evaluated 70 randomized controlled trials with a combined enrollment of over 26,000 participants and concluded that "tretinoin 0.025% to 0.05% cream applied once daily significantly reduced both inflammatory and non-inflammatory acne lesions compared with vehicle, with a mean lesion count reduction of 40% to 70% over 12 weeks" [12]. The number needed to treat (NNT) for achieving at least a 50% reduction in total lesion count was 4.

For photoaging, a key multicenter trial published in the New England Journal of Medicine randomized 251 patients to tretinoin 0.05% emollient cream versus vehicle for 24 weeks [13]. Tretinoin-treated patients showed statistically significant improvement in fine wrinkling (P<0.001), coarse wrinkling, and skin laxity. The study also demonstrated sustained benefit at a 48-week follow-up for patients who continued treatment.

Regarding safety, the most common adverse effects are local: erythema, peeling, dryness, and a transient worsening of acne during the first two to four weeks (the so-called "retinoid purge"). A pooled safety analysis of over 5,000 patients treated with tretinoin found that fewer than 3% discontinued due to adverse effects [14]. Tretinoin is classified as FDA Pregnancy Category X. Women of reproductive age must use effective contraception during treatment.

Dr. Albert Kligman's original observation was straightforward: "Tretinoin reverses many of the histologic features of photodamage by stimulating new collagen synthesis and normalizing keratinocyte differentiation" [1]. That mechanism remains the accepted explanation for tretinoin's anti-aging effects.

Choosing the Right Strength and Formulation

Tretinoin is available in three standard concentrations (0.025%, 0.05%, and 0.1%) and two primary vehicles (cream and gel). The right choice depends on skin type, treatment goal, and tolerance.

Most dermatologists start patients on 0.025% cream. This lowest concentration minimizes initial irritation while still delivering clinically meaningful results. A 2020 study in the British Journal of Dermatology found that 0.025% tretinoin cream produced a 43% reduction in inflammatory lesion count at 12 weeks, compared with 61% for 0.05% [15]. The difference was statistically significant, but the lower concentration also had a 40% lower rate of moderate-to-severe irritation.

Gel formulations suit oily or acne-prone skin better than creams because they contain less emollient and do not leave a greasy film. Creams are better for patients with dry or sensitive skin, or for those treating photoaging rather than acne. Microsphere formulations (Retin-A Micro) use a controlled-release delivery system that reduces peak skin irritation but cost significantly more.

Dose escalation follows a standard protocol. Start at 0.025% nightly for four to six weeks. If tolerated with minimal irritation, increase to 0.05%. Reserve 0.1% for patients with severe acne who tolerate the intermediate strength. The American Academy of Dermatology's acne guidelines recommend this stepwise approach [4].

One practical tip: apply tretinoin to completely dry skin, at least 20 minutes after washing. Applying to damp skin increases absorption and irritation. A pea-sized amount covers the entire face.